Luminal breast cancer, defined as hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[−]) tumors, is the most common (~65%) subtype in postmenopausal patients with advanced breast cancer (ABC). Here, NR4A1 is linked to breast cancer.